Results 31 to 40 of about 3,260 (145)

Zanubrutinib: past, present, and future

, 2023
In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be approved, and it changed the standard-of-care treatment for ...
Constantine S. Tam, Javier L. Muñoz, John F. Seymour, Stephen Opat   +3 more
core   +1 more source

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

Pharmacology Research & Perspectives, 2021
Zanubrutinib is a highly selective, potent, orally available, targeted covalent inhibitor (TCI) of Bruton's tyrosine kinase (BTK). This work investigated the in vitro drug metabolism and transport of zanubrutinib, and its potential for clinical drug–drug
Heather Zhang, Ying C. Ou, Dan Su, Fan Wang, Lai Wang, Srikumar Sahasranaman, Zhiyu Tang   +6 more
doaj   +1 more source

Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib

Frontiers in Medicine, 2022
PurposeTo report a case of primary vitreoretinal lymphoma (PVRL) treated with oral zanubrutinib, who had bilateral intraocular hemorrhage after intravitreal injection of methotrexate (MTX).Case reportA 69-year-old Chinese female presented with vision ...
Xiao Zhang, Xiao Zhang, Rongping Dai, Rongping Dai, Chan Zhao, Chan Zhao, Meifen Zhang, Meifen Zhang   +7 more
doaj   +1 more source

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia [PDF]

The phase 3 ASPEN trial (NCT03053440) compared Bruton tyrosine kinase inhibitors (BTKis), zanubrutinib and ibrutinib, in patients with Waldenström macroglobulinemia (WM).
Tani, M, Tam, CS, Buske, C, Wahlin, BE, Leblond, V, Libby, E, Belada, D, Schneider, J, Cull, G, Czyz, J, Minnema, MC, Cohen, A, Motta, M, Tedeschi, A, Dimopoulos, MA, Shen, Z, Chan, WY, García-San, R, Opat, S, Jurczak, W, D'Sa, S, Mulligan, S, De Larrea, CF, Matous, J, Owen, RG, Castillo, JJ, Treon, SP, Siddiqi, T, Trotman, J, Wu, B, Allewelt, H, Yu, Y, Trnený, M, McCarthy, H, Marlton, P, Lee, HP   +35 more
core   +6 more sources

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series

Frontiers in Oncology, 2021
Zanubrutinib is a second-generation Bruton’s tyrosine kinase inhibitor. Its safety and effectiveness in central nervous system (CNS) lymphoma along with its distribution in the brain and ability to cross the blood–brain barrier (BBB) remain unknown. This
Yan Zhang, Yanan Li, Zhe Zhuang, Wei Wang, Chong Wei, Danqing Zhao, Daobin Zhou, Wei Zhang   +7 more
doaj   +1 more source

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma [PDF]

, 2021
Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was ...
Simpson, D, Tam, CS, Opat, S, et al,, Cull, G   +4 more
core   +2 more sources

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

Clinical and Translational Science, 2021
Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory ...
Ying C. Ou, Lucy Liu, Bilal Tariq, Kun Wang, Ashutosh Jindal, Zhiyu Tang, Yuying Gao, Srikumar Sahasranaman   +7 more
doaj   +1 more source

Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib. [PDF]

First-generation Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been associated with an increased risk of cardiovascular toxicities. Zanubrutinib is a more selective, next-generation BTK inhibitor.
Flowers, Christopher, Chen, Lipeng, Brown, Jennifer, Moslehi, Javid, Cohen, Aileen, Furman, Richard, Zhang, Meng, Salem, Joe-Elie, Ma, Han, Zhang, Jun, Tam, Constantine   +10 more
core   +2 more sources

Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo

Technology in Cancer Research & Treatment, 2022
Background and Objects: Bruton's tyrosine kinase inhibitors are commonly used and effective for lymphoma and chronic lymphocytic leukemia (CLL). Ibrutinib might improve the effect of anti-cluster of differentiation 19 (CD19) chimeric antigen receptor ...
Xiupeng Ye, Meijing Liu, Cuicui Lv, Yeqiong Li, Lan Chen, Jin Zhang, Juan Mu, Qi Deng   +7 more
doaj   +1 more source

Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab [PDF]

, 2023
Zanubrutinib is a highly selective, next-generation Bruton’s tyrosine kinase inhibitor. In the phase 3 SEQUOIA trial (NCT03336333), treatment with zanubrutinib resulted in significantly improved progression-free survival compared to bendamustine plus ...
Paolo Ghia (760385), Andy Szeto (12414155), Mazyar Shadman (17246), Constantine S. Tam (11567259), Jason C. Paik (15000906), Jennifer R. Brown (228154), Brad S. Kahl (15016011), Tadeusz Robak (21515), Keri Yang (10803767), Gisoo Barnes (782653), Tian Tian (170088)   +10 more
core   +2 more sources